Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have been given a consensus rating of “Moderate Buy” by the ten brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $87.3750.

KNSA has been the subject of a number of recent analyst reports. Weiss Ratings upgraded shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, July 29th. The Goldman Sachs Group boosted their price target on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. upped their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Jefferies Financial Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Finally, Citigroup raised their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, Director G Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the transaction, the director directly owned 11,672 shares in the company, valued at approximately $950,450.96. This trade represents a 23.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 51.98% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Several institutional investors have recently modified their holdings of KNSA. Qube Research & Technologies Ltd boosted its stake in Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares in the last quarter. Rubric Capital Management LP raised its position in Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after acquiring an additional 526,567 shares in the last quarter. Bank of America Corp DE raised its position in Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after acquiring an additional 506,576 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Kiniksa Pharmaceuticals International by 213.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after acquiring an additional 447,536 shares during the last quarter. Finally, Spruce Street Capital LP acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $17,943,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA stock opened at $78.15 on Thursday. Kiniksa Pharmaceuticals International has a 1 year low of $32.69 and a 1 year high of $82.94. The firm has a market capitalization of $6.10 billion, a PE ratio of 80.57 and a beta of 0.05. The stock has a fifty day moving average of $63.28 and a two-hundred day moving average of $53.26.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, meeting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%.The company had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. Equities research analysts predict that Kiniksa Pharmaceuticals International will post 1.37 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.